hVIVO Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

hVIVO şirketinin toplam hissedar öz sermayesi £38.5M ve toplam borcu £0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £87.7M ve £49.3M dir. hVIVO 'in FAVÖK'ü £13.3M faiz karşılama oranı -16.9 dur. Şirketin £37.1M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	-16.9x
Nakit	UK£37.09m
Eşitlik	UK£38.46m
Toplam yükümlülükler	UK£49.28m
Toplam varlıklar	UK£87.75m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CRO 'nin kısa vadeli varlıkları ( £57.8M ) kısa vadeli yükümlülüklerini ( £36.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: CRO şirketinin kısa vadeli varlıkları ( £57.8M ) uzun vadeli yükümlülüklerini ( £13.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CRO borçsuzdur.

Borcun Azaltılması: CRO şirketinin 5 yıl önce borç/öz sermaye oranı 23.1% iken borcu yok.

Borç Kapsamı: CRO un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: CRO şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

hVIVO Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

hVIVO Proposes Cancellation of Admission to Trading on Euronext Growth

Recent updates

hVIVO plc to Report First Half, 2024 Results on Sep 10, 2024

hVIVO Proposes Cancellation of Admission to Trading on Euronext Growth

hVIVO plc, Annual General Meeting, May 13, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: UK£0.024 (vs UK£0.001 loss in FY 2022)

hVIVO plc to Report Fiscal Year 2023 Results on Apr 09, 2024

hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.

hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.

Now 22% undervalued

hVIVO plc Signs £6.3 Million Human Challenge Study Model

hVIVO plc Increases Revenue Guidance for 2023

hVIVO plc to Report First Half, 2023 Results on Sep 12, 2023

hVIVO plc to Develop Human Metapneumovirus Challenge Model

Full year 2022 earnings released: UK£0.001 loss per share (vs UK£0 in FY 2021)

Forecast to breakeven in 2023

hVIVO plc Provides Earnings Guidance for the Full Year 2022

Forecast breakeven date pushed back to 2023

hVIVO plc Announces Publication of Imutex Phase I Data

Now 20% undervalued

Less than half of directors are independent

Open Orphan plc Announces Chief Financial Officer Changes

Open Orphan plc Announces Positive Data from Peer-Reviewed Study Evaluating the in Vitro Efficacy of Flu-V

First half 2022 earnings released: EPS: UK£0 (vs UK£0.002 in 1H 2021)

Open Orphan plc Reiterates Revenue Guidance for the Full Year of 2022

Open Orphan Plc to Report First Half, 2022 Results on Sep 08, 2022

Open Orphan plc, Annual General Meeting, Jul 05, 2022

Full year 2021 earnings released: EPS: UK£0 (vs UK£0.018 loss in FY 2020)

Open Orphan plc Appoints Martin Gouldstone as Independent Non-Executive Director

Open Orphan plc to Report Fiscal Year 2021 Results on Jun 07, 2022

Less than half of directors are independent

Open Orphan plc Announces Characterisation Study Results in Nature Medicine

Open Orphan plc Appoints Yamin 'Mo' Khan as Chief Executive Officer

First half 2021 earnings released: EPS UK£0.002 (vs UK£0.012 loss in 1H 2020)

Executive Chairman recently bought €352k worth of stock

Full year 2020 earnings released: UK£0.018 loss per share (vs UK£0.034 loss in FY 2019)

New 90-day high: €0.35

Open Orphan plc Announces Ethics Approval for Covid-19 Human Challenge Study

Open Orphan Plc's Subsidiary Venn Life Sciences Announces Contract Extension with Carna Biosciences

New 90-day high: €0.33

Open Orphan plc Announces Contract Renewal with Top-3 Pharmaceutical Client Extending Its Consultancy Services to End of December 2021

Open Orphan plc Announces Board Changes, Effective on December 31, 2020

Open Orphan plc Announces the Signs of A £2.5 Million Contract by hVIVO

New 90-day high: €0.21

New 90-day high: €0.20

Open Orphan plc Announces £4.3 Million Contract to Conduct Human Viral Challenge Study

Open Orphan plc to Report First Half, 2020 Results on Sep 30, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin